BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

Abivax and Immunic are launching COVID-19 trials of their autoimmune therapies in France and Germany, respectively, meeting regulators’ demands for large, controlled studies to demonstrate therapeutic efficacy. In the U.S., the patent office is fast-tracking...
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells. Announced Tuesday, the cash infusion includes €28 million ($31.4...
BC Innovations | Sep 27, 2018
Translation in Brief

Twice as splice

Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and...
BC Week In Review | Sep 7, 2018
Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
BC Week In Review | Jan 12, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BC Extra | Jan 10, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BC Week In Review | Oct 6, 2017
Clinical News

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy...
BC Week In Review | Sep 15, 2017
Company News

Evotec and Abivax partner to target infectious diseases

Evotec AG (Xetra:EVT) and Abivax S.A.S. (Euronext Paris:ABVX) partnered to discover and develop compounds to treat viral infectious including respiratory syncytial virus (RSV), influenza and dengue fever. Abivax will identify targets and use its antiviral...
Items per page:
1 - 10 of 31
BioCentury | May 20, 2020
Product Development

BARDA takes steps to secure supply chain as more companies look to scale up manufacturing

HHS is taking steps to shore up the U.S.’s national supply chain and manufacturing capabilities after global disruptions in the early days of the COVID-19 crisis. The agency’s BARDA has closed a four-year, $354 million...
BioCentury | May 15, 2020
Product Development

Repurposed autoimmune therapies head for controlled COVID-19 studies in Europe

Abivax and Immunic are launching COVID-19 trials of their autoimmune therapies in France and Germany, respectively, meeting regulators’ demands for large, controlled studies to demonstrate therapeutic efficacy. In the U.S., the patent office is fast-tracking...
BioCentury | Dec 19, 2019
Finance

Truffle’s recipe for company creation

Paris-based Truffle Capital has closed its €250 million ($277.9 million) BioMedTech fund to create new drug and medtech companies and nurture them through at least Phase II testing. The fund will channel around 30% of...
BioCentury | Jun 18, 2019
Finance

Imcyse to test cell killing approach in autoimmune disease with €35M in new funding

With €35 million ($39.2 million) in new funding, Imcyse hopes to obtain clinical proof of concept for its modified peptide approach to killing autoimmune disease-causing cells. Announced Tuesday, the cash infusion includes €28 million ($31.4...
BC Innovations | Sep 27, 2018
Translation in Brief

Twice as splice

Abivax S.A. (Euronext:ABVX) has positioned its anti-HIV therapy ABX464 to take on inflammatory diseases after discovering the small molecule triggers RNA splicing that both halts HIV viral replication and boosts anti-inflammatory responses in HIV and...
BC Week In Review | Sep 7, 2018
Clinical News

Abivax's ABX464 improves mucosal healing, Mayo Score in Phase IIa for UC

Abivax S.A. (Euronext:ABVX) said ABX464 improved mucosal healing rate (50% vs. 11%, p=0.03) and reduced partial (62% vs. 32%, p<0.02) and total Mayo Scores (53% vs. 37%, p<0.03) at eight weeks vs. placebo in 29...
BC Week In Review | Jan 12, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BC Extra | Jan 10, 2018
Financial News

Truffle Capital raises $102M toward life science and medtech fund

Life sciences and information technology VC Truffle Capital raised $102 million toward its planned $240 million Truffle BioMedTech fund in an initial closing. The Paris-based firm said it remains on track to raise the remaining...
BC Week In Review | Oct 6, 2017
Clinical News

Abivax's ABX464 reduces HIV DNA in CD4+ T cells in Phase IIa

Abivax S.A. (Euronext:ABVX) reported top-line data from 9 HIV-infected patients in the first cohort of the open-label, Spanish Phase IIa ABX464-005 trial showed that once-daily 150 mg oral ABX464 for 28 days plus antiretroviral therapy...
BC Week In Review | Sep 15, 2017
Company News

Evotec and Abivax partner to target infectious diseases

Evotec AG (Xetra:EVT) and Abivax S.A.S. (Euronext Paris:ABVX) partnered to discover and develop compounds to treat viral infectious including respiratory syncytial virus (RSV), influenza and dengue fever. Abivax will identify targets and use its antiviral...
Items per page:
1 - 10 of 31